Sign In
Buy ROG
$148.00
-6.22 (-4.03%)
At Close: Jun 03, 2026
Rogers Corp. (ROG) Q1 Earnings and Revenues Surpass Estimates
10:15pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Rogers Corp. (ROG) delivered earnings and revenue surprises of 34.21% and 6.55%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Can a decades-old antidepressant keep COVID-19 patients out of the hospital?
01:00pm, Thursday, 28'th Apr 2022 MarketWatch
It's one of several generic drugs that's being tested as a way to treat the virus.
[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche mit gutem Verkaufswachstum im ersten Quartal 2022
05:00am, Monday, 25'th Apr 2022 GlobeNewswire Inc.
Basel, 25. April 2022
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth in the first quarter of 2022
05:00am, Monday, 25'th Apr 2022 GlobeNewswire Inc.
[Annonce événementielle selon l’art. 53 RC] Roche affiche une bonne croissance des ventes au premier trimestre 2022
05:00am, Monday, 25'th Apr 2022 GlobeNewswire Inc.
Bâle, le 25 avril 2022
CHMP recommends EU approval of Roche’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer
03:22pm, Friday, 22'nd Apr 2022 GlobeNewswire Inc.
Basel, 22 April 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approva
CHMP recommends EU conditional approval of Roche’s potential first-in-class bispecific antibody mosunetuzumab for people with relapsed or refractory follicular lymphoma
03:20pm, Friday, 22'nd Apr 2022 GlobeNewswire Inc.
Basel, 22 April 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval under co
Is Vanguard International Dividend Appreciation ETF (VIGI) a Strong ETF Right Now?
10:20am, Friday, 22'nd Apr 2022 Zacks Investment Research
Smart Beta ETF report for VIGI
2 Unstoppable Green Flags for AbbVie
11:00am, Thursday, 14'th Apr 2022 The Motley Fool
There's a silver lining around an approaching dark cloud.
U.S. FDA grants priority review to Roche’s Actemra/RoActemra for the treatment of COVID-19 in hospitalised adults
05:03am, Monday, 04'th Apr 2022 GlobeNewswire Inc.
Basel, 04 April 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA
New data for Roche’s OCREVUS (ocrelizumab) show benefit in disability progression and cognitive decline in both secondary progressive and primary progressive multiple sclerosis
05:00am, Monday, 04'th Apr 2022 GlobeNewswire Inc.
Basel, 04 April 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new OCREVUS® (ocrelizumab) data that show its benefit on disease progression and cognitive outcomes in primary progressive mu
Ad hoc announcement pursuant to Art. 53 LR Roche provides update on phase III SKYSCRAPER-02 study in extensive-stage small cell lung cancer
05:00am, Wednesday, 30'th Mar 2022 GlobeNewswire Inc.
Ad hoc announcement pursuant to Art. 53 LR
Which Company Has the Biggest COVID Program? The Answer Isn't Moderna.
12:00pm, Sunday, 27'th Mar 2022 The Motley Fool
Another player has stuffed its pipeline with many coronavirus candidates.
CHMP recommends EU approval of Roche’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma
12:45pm, Friday, 25'th Mar 2022 GlobeNewswire Inc.
Basel, 25 March 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of P
Roche to present data across broad and impactful neuroscience portfolio at 2022 AAN Annual Meeting
06:00am, Friday, 25'th Mar 2022 GlobeNewswire Inc.
Basel, 25 March 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data for its approved and investigational medicines across neurological disorders will be presented at the 74th American A
